410 articles about Cencora
Outlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMD
Outlook Therapeutics, Inc. and AmerisourceBergen announced today that they have entered into a strategic relationship in preparation for the anticipated commercial launch in the United States of ONS-5010 / LYTENAVA™ (bevacizumab-vikg), if approved by the U.S. Food and Drug Administration (FDA).
AmerisourceBergen Corporation (NYSE: ABC) today announced that it has signed a definitive agreement to acquire PharmaLex Holding GmbH, a leading provider of specialized services for the life sciences industry, from funds advised by AUCTUS Capital Partners AG for €1.28 billion in cash, subject to certain customary adjustments.
AmerisourceBergen Hosts Inaugural Disparities in Cancer Care Summit.
AmerisourceBergen to Launch Digital Therapeutics Platform to Facilitate Access to Innovative Products
As the pipeline of digital therapeutics (DTx) continues to expand, AmerisourceBergen today announced plans to launch DTx Connect.
AmerisourceBergen Corporation (NYSE: ABC) today announced that it plans to release its results for the Third Quarter of Fiscal 2022 on Wednesday, August 3, 2022, prior to the opening of trading on the New York Stock Exchange.
The AmerisourceBergen Foundation , an independent not-for-profit charitable giving organization focused on supporting health-related causes that enrich the global community, has committed $150,000 to the United Nations Foundation ’s Shot@Life campaign to support vaccine equity.
AmerisourceBergen Corporation hosted an investor day event in New York City. Steven H. Collis, Chairman, President & Chief Executive Officer; James F. Cleary, EVP & Chief Financial Officer; Bob Mauch, EVP & Group President; and Susan Lorenz-Fisher, SVP, Corporate Responsibility & Sustainability, discussed the company’s purpose, strategic imperatives, ESG commitments, and long-term financial growth outlook.
AmerisourceBergen Investor Day to Highlight Strategic Imperatives and Provide Long-Term Financial Outlook
AmerisourceBergen Corporation reiterated its previously provided guidance for fiscal year 2022 and announced that its Board of Directors has authorized a new share repurchase program.
AmerisourceBergen Launches Clinical Trial Navigator to Bolster Equitable and Accessible Community-Based Research Opportunities Nationwide
AmerisourceBergen Launches Clinical Trial Navigator to Bolster Equitable and Accessible Community-Based Research Opportunities Nationwide.
AmerisourceBergen Corporation (NYSE: ABC) today announced that it is resuming share repurchases with excess free cash flow in accordance with the company’s disciplined approach to capital allocation.
AmerisourceBergen Corporation reported that in its fiscal year 2022 second quarter ended March 31, 2022, revenue increased 17.4 percent year-over-year to $57.7 billion.
AmerisourceBergen & Biopharmaceutical Companies Discuss Strategies to Advance Pharmaceutical Innovation and Access at ThinkLive Commercialization Conference
AmerisourceBergen & Biopharmaceutical Companies Discuss Strategies to Advance Pharmaceutical Innovation and Access at ThinkLive Commercialization Conference.
AmerisourceBergen, a global healthcare company, announces a program designed to help hospitals and health systems launch or optimize home infusion service lines.
AmerisourceBergen Partners with Chronicled to Optimize Pharmaceutical Chargeback Accuracy Using Blockchain-Powered Technology
Global healthcare company AmerisourceBergen (AB) announced today its partnership with Chronicled , the administrator of the MediLedger Network, to leverage a new blockchain-powered solution designed to enhance pharmaceutical chargeback accuracy and significantly reduce chargeback rejections.
AmerisourceBergen, a global healthcare solutions company, today announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will invest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals globally.
AmerisourceBergen & Good Neighbor Pharmacy Surpass 5 Million Vaccine Doses Allocated through its Federal Retail Pharmacy Program for COVID-19 Vaccination
AmerisourceBergen & Good Neighbor Pharmacy Surpass 5 Million Vaccine Doses Allocated through its Federal Retail Pharmacy Program for COVID-19 Vaccination.
AmerisourceBergen Announces Date and Time for Second Quarter Fiscal 2022 Earnings Release; Announces 2022 Investor Day
AmerisourceBergen Corporation announced that it plans to release its results for the Second Quarter of Fiscal 2022 on Wednesday, May 4, 2022, prior to the opening of trading on the New York Stock Exchange.
AmerisourceBergen announced today that each company has independently determined that there is sufficient participation by states and litigating political subdivisions to proceed with a comprehensive agreement to settle the vast majority of the opioid lawsuits filed by state and local governmental entities.
AmerisourceBergen Adds Freight Management Capabilities Powered by TRIOSE, Inc. for Hospital & Health System Customers
Today, global healthcare company AmerisourceBergen announced the addition of TRIOSE ’s freight management capabilities to its suite of commercial solutions.
Cancer Specialists of North Florida Continues Long-Term Strategic Relationship with AmerisourceBergen
AmerisourceBergen, a global healthcare solutions leader, announced that it has reached an agreement to extend its strategic relationship with Cancer Specialists of North Florida, an oncology provider with the largest cancer practice in Jacksonville, specializing in medical oncology, radiation oncology, hematology and diagnostic imaging.